Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 31;69(Suppl 2):S49–S57. doi: 10.1093/cid/ciz472

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — Annual proportion of confirmed Streptococcus pneumoniae meningitis cases due to vaccine serotypes by pneumococcal conjugate vaccine (PCV) formulation, 2011–2016. A, Proportion of confirmed S. pneumoniae meningitis cases due to 10-valent PCV (PCV10) serotypes in countries that introduced PCV10 (n = 4), by year. Of the 6 countries that introduced PCV10, 4 contributed confirmed cases for this analysis: Ethiopia (n = 22), Madagascar (n = 66), Uganda (n = 106), and Zambia (n = 76). Confirmed cases from the following countries were excluded: data unavailable for all surveillance years (Mozambique); ≤65% PCV coverage for at least 2 consecutive years (Nigeria). The percentage of PCV10 serotypes was determined by the number of reported PCV10 serotypes/all reported serotype results in a year: 2011 (7/9); 2012 (31/58); 2013 (48/68); 2014 (20/42); 2015 (26/58); 2016 (13/35). B, Proportion of confirmed S. pneumoniae meningitis cases due to 13-valent PCV (PCV13) serotypes in countries that introduced PCV13 (n = 8), by year. Of 20 countries that introduced PCV13, 8 were included in this analysis: Benin (n = 20), Cameroon (n = 17), Ghana (n = 8), Senegal (n = 26), Kingdom of Eswatini (formerly Swaziland, n = 3), Togo (n = 22), United Republic of Tanzania (n = 2), and Zimbabwe (n = 21). Confirmed cases from the following countries were excluded: data unavailable for all surveillance years (Angola, Central African Republic, Cote d’Ivoire, Malawi, Sierra Leone); at least 2 years of data not available following vaccine introduction (Lesotho); ≤65% PCV coverage for at least 2 consecutive years (Niger); PCV not introduced during the surveillance period (Gambia, Rwanda); and/or did not report any S. pneumoniae serotyping data (Angola, Burkina Faso, Burundi, Central African Republic, Democratic Republic of Congo, Malawi). The percentage of PCV13 serotypes was determined by the number of reported PCV13 serotypes/all reported serotype results in a year: 2011(18/20); 2012 (18/28); 2013 (10/16); 2014 (14/32); 2015 (8/12); 2016 (5/11). Dashed blue line indicates the trend line. Abbreviations: PCV10, 10-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.